Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.
External link for Orionis Biosciences
950 Winter St
Waltham, Massachusetts 02451, US
Technologiepark 94
Gent, 9052, BE
Orionis Biosciences reposted this
🏆 Thrilled to announce that our collaboration with Orionis Biosciences has been honored as the Alliance of the Year 2023 by In Vivo! This recognition underscores our dedication to forging groundbreaking partnerships, exemplified by our work with partners like Orionis Biosciences to discover molecular glues. Excited to propel the boundaries of science forward in this transformative space! #Innovation #Partnership https://lnkd.in/drfkNrse
Orionis Biosciences reposted this
The Genentech/Orionis deal was selected as a finalist in In Vivo's "Deals of the Year" contest - Please feel free to vote for us 😊 in the "Top Alliances of 2023" category 🤗 https://lnkd.in/eYwUEdwS
Orionis Biosciences reposted this
Two important company announcements today! 1: New milestone reached with our first-in-class, targeted interferon A-Kine®, ORB-011. First cancer patient dosed in a Phase 1 immunotherapy clinical trial for advanced solid tumors. 2: Tony Fadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more here: https://lnkd.in/gegFNATk #immunotherapy #cancerresearch #clinicaltrials #solidtumors
Thank you Tony Fadell for your support. We’re very excited to have you join the board and help us navigate the future! And a big thank you also to Matias de Tezanos for having been an incredibly supportive board member over the past years, and for continuing to be part of the journey. Exciting times ahead!
Two important company announcements today! 1: New milestone reached with our first-in-class, targeted interferon A-Kine®, ORB-011. First cancer patient dosed in a Phase 1 immunotherapy clinical trial for advanced solid tumors. 2: Tony Fadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more here: https://lnkd.in/gegFNATk #immunotherapy #cancerresearch #clinicaltrials #solidtumors
Two important company announcements today! 1: New milestone reached with our first-in-class, targeted interferon A-Kine®, ORB-011. First cancer patient dosed in a Phase 1 immunotherapy clinical trial for advanced solid tumors. 2: Tony Fadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more here: https://lnkd.in/gegFNATk #immunotherapy #cancerresearch #clinicaltrials #solidtumors
If you would like a great deep-dive on everything Orionis Biosciences, tune into this interview between our CEO Nikolai Kley and Brad Loncar of BiotechTV. Over 20 minutes you'll hear about how our drug discovery and design platforms, inspired by powerful biological mechanisms present in nature, can reach undruggable targets with molecular glues, and restart a stalled Cancer Immunity Cycle with targeted cytokines. https://lnkd.in/eg8bM_EF
Genentech sticks molecular glue deal with Orionis for $47M upfront
Orionis Biosciences reposted this
Very cool to see a second collaboration on Molecular Glue discovery with Orionis, here with Roche-Genentech. Niko and friends are creative scientists, terrific partners at the bench. Proud to see this platform expand its potential impact. https://lnkd.in/eGGTJVqv
Genentech gets gluey, paying $47M upfront to Orionis Biosciences for degrader discovery deal
Orionis Biosciences reposted this
Very exciting news!! Very proud of the amazing teamwork at Orionis Biosciences, many efficient glue concepts at work, and to partner with Genentech! A Big Thank You also to the remarkable, highly collaborative, and visionary Genentech team. Looking forward to new discoveries to advance potentially transformative glue class medicines https://orb.ink/2023_AG #cancer #cancerresearch #biotech